https://openbell.ai/ 2026-09-18T12:14:43.475Z hourly 1.0 https://openbell.ai/support 2026-09-18T12:14:43.475Z monthly 0.7 https://openbell.ai/privacy 2026-09-18T12:14:43.475Z monthly 0.5 https://openbell.ai/terms 2026-09-18T12:14:43.475Z monthly 0.5 https://openbell.ai/feed.json 2026-09-18T12:14:43.475Z hourly 0.8 https://openbell.ai/news/ONON:1789733409118 2026-09-18T12:10:09.118Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Mbappé Signs for On’s Push Into Football in Blow for Nike' - Bloomberg Kylian Mbappé has signed a deal with On, marking a significant move for the company as it expands into the football sector, which poses a challenge to Nike's dominance in sports apparel. This partnership is expected to enhance On's brand visibility and market presence in the competitive football industry. The financial implications of this deal for both On and Nike could impact their respective stock performances. https://openbell.ai/news/OSCR:1789733353648 2026-09-18T12:09:13.648Z daily 0.9 https://cdn.brandfetch.io/OSCR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Raymond James Maintains Outperform on Oscar Health, Raises Price Target to $42 Raymond James analyst John Ransom has maintained an 'Outperform' rating on Oscar Health (NYSE: OSCR) and raised the price target from $34 to $42. This adjustment reflects a positive outlook for the company in the market. https://openbell.ai/news/XRTX:1789733314587 2026-09-18T12:08:34.587Z daily 0.9 https://cdn.brandfetch.io/XRTX/w/400/h/400?c=1idopYfmtR7ZKg8QMud XORTX Outlines Anticipated FDA IND Submission For XRx-026 Gout Program XORTX Therapeutics Inc. (NASDAQ: XRTX) is preparing to submit an Investigational New Drug (IND) application to the FDA for its XRx-026 gout program, with a target submission date in the fourth quarter of 2026. The company plans to conduct a two-part clinical study, XRX-OXY-102, to gather necessary data for a future New Drug Application (NDA). If successful, XORTX aims to request a pre-NDA meeting and submit the NDA within a year, addressing a potential market opportunity of approximately $700 million annually. https://openbell.ai/news/BTCUSD:1789733199781 2026-09-18T12:06:39.781Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/BlackRock.jpg?width=250&height=187 Bitcoin's Much Less Volatile Than It Used to Be. BlackRock Says It Played a Part in That. Bitcoin (CRYPTO: BTC) has experienced reduced volatility, with its range compressing from around 80 to 35-40, according to BlackRock's Head of U.S. Equity ETFs, Jay Jacobs. This stabilization is attributed to the introduction of BlackRock's IBIT product, which has made Bitcoin more accessible to institutional investors. The firm is focusing on Bitcoin and Ethereum, which together represent a significant portion of the digital asset market cap, before expanding its crypto offerings. https://openbell.ai/news/SSM:1789733167027 2026-09-18T12:06:07.027Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Consumer Discretionary Stocks Moving In Friday's Pre-Market Session In Friday's pre-market session, Sono Gr (NASDAQ: SSM) saw a significant increase of 60.3%, reaching $2.34, with a market value of $2.1 million. Other notable gainers included Foresight Autonomous (NASDAQ: FRSX) up 11.32% to $1.18 and On Holding (NYSE: ONON) rising 7.02% to $29.25, with market caps of $3.1 million and $9.5 billion, respectively. Conversely, Digital Currency X (NASDAQ: DCX) experienced the largest decline, falling 18.0% to $0.36, with a market value of $154.7 million. https://openbell.ai/news/IMCC:1789733166793 2026-09-18T12:06:06.793Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Health Care Stocks Moving In Friday's Pre-Market Session In Friday's pre-market session, IM Cannabis (NASDAQ: IMCC) saw a significant stock increase of 108.5%, reaching $3.63, with a market value of $1.0 million. Other notable gainers included Alaunos Therapeutics (NASDAQ: TCRT), which rose 41.87% to $2.27, and DataMEDS AI (NASDAQ: MEDS), up 25.64% to $5.83. Conversely, Xenon Pharmaceuticals (NASDAQ: XENE) experienced the largest decline, falling 23.3% to $44.0, while OraSure Technologies (NASDAQ: OSUR) dropped 14.05% to $3.0. https://openbell.ai/news/CTNT:1789733166531 2026-09-18T12:06:06.531Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=250&height=187 12 Industrials Stocks Moving In Friday's Pre-Market Session In Friday's pre-market session, Cheetah Net Supply Chain (NASDAQ: CTNT) shares surged by 26.0% to $0.06. Other notable gainers included Svrn (NASDAQ: SVRN), which rose 12.75% to $16.0, and Zenta Group Co (NASDAQ: ZTG), up 11.66% to $1.34. Conversely, Stardust Power (NASDAQ: SDST) experienced a significant decline of 32.6%, falling to $0.17, while Huachen AI Parking Mgmt (NASDAQ: HCAI) dropped 19.48% to $0.49. https://openbell.ai/news/USDE:1789733166301 2026-09-18T12:06:06.301Z daily 0.9 https://cdn.benzinga.com/files/images/story/2025/11/06/movers_4.jpg?width=250&height=187 12 Information Technology Stocks Moving In Friday's Pre-Market Session In Friday's pre-market session, StableCoinX (NASDAQ: USDE) saw a significant gain of 19.7%, reaching $9.23, with a market value of $185.2 million. Other notable gainers included Viant Technology (NASDAQ: DSP), which rose 13.77% to $11.4, and Alpha & Omega (NASDAQ: AOSL), which increased by 6.26% to $26.79. Conversely, Abits Group (NASDAQ: ABTS) experienced the largest decline, dropping 23.5% to $1.09, while CID Holdco (NASDAQ: DAIC) fell by 20.76% to $4.2. https://openbell.ai/news/AGMH:1789733147793 2026-09-18T12:05:47.793Z daily 0.9 https://cdn.brandfetch.io/AGMH/w/400/h/400?c=1idopYfmtR7ZKg8QMud AGM Group Holdings Announces Share Purchase Agreement With Unnamed Investor For Up To $11M In Class A Shares At $0.6305/Share AGM Group Holdings has entered into a share purchase agreement with an unnamed investor for the acquisition of up to $11 million in Class A shares, priced at $0.6305 per share. This strategic move is expected to enhance the company's capital structure and provide additional financial flexibility. The announcement may impact AGMH's stock performance as it reflects investor interest and potential growth opportunities. https://openbell.ai/news/CHSN:1789733071668 2026-09-18T12:04:31.668Z daily 0.9 https://cdn.brandfetch.io/CHSN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chanson International H1 EPS $0.64 Up From $(286.93) YoY, Sales $8.296M Down From $8.688M YoY Chanson International (NASDAQ: CHSN) reported earnings of $0.64 per share for the first half of the year, a significant recovery from a loss of $(286.93) per share in the same period last year. However, the company's sales decreased by 4.51% to $8.296 million, down from $8.688 million year-over-year. https://openbell.ai/news/PM:1789733006776 2026-09-18T12:03:26.776Z daily 0.9 https://cdn.brandfetch.io/PM/w/400/h/400?c=1idopYfmtR7ZKg8QMud Philip Morris International Increases Quarterly Dividend From $1.47/Share To $1.60/Share openbell Financial News https://openbell.ai/news/JOBY:1789732951458 2026-09-18T12:02:31.458Z daily 0.9 https://cdn.brandfetch.io/JOBY/w/400/h/400?c=1idopYfmtR7ZKg8QMud Joby Aviation Says Aircraft Equipped With Its Autonomy Technology Completes First-Ever Autonomous Flight Across US Joby Aviation, Inc. (NYSE: JOBY) announced that its aircraft equipped with autonomy technology has successfully completed the first-ever autonomous flight across the United States, covering 3,199 miles without any control inputs from the onboard safety pilot. The flight, which included autonomous taxi, takeoff, cruise, and landing, was remotely supervised from over 2,300 miles away. This milestone highlights the operational maturity and safety of Joby's technology, which has potential applications in commercial freight, emergency response, and defense logistics. https://openbell.ai/news/CORT:1789732926498 2026-09-18T12:02:06.498Z daily 0.9 https://cdn.brandfetch.io/CORT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Corcept Therapeutics Says CHMP Recommends EU Approval Of Relacorilant With Nab-Paclitaxel For Platinum-Resistant Ovarian Cancer; EC Decision Expected In Q4 2026 openbell Financial News https://openbell.ai/news/ELAB:1789732901572 2026-09-18T12:01:41.572Z daily 0.9 https://cdn.brandfetch.io/ELAB/w/400/h/400?c=1idopYfmtR7ZKg8QMud PMGC Holdings Announces Payment Agreement With Longevity Health Securing $94,937 In 2025 Elevai Skincare Royalties, $10K Monthly Installments Through August 2031 openbell Financial News https://openbell.ai/news/XENE:1789732865985 2026-09-18T12:01:05.985Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Section-Of-A-Financial-Newspaper-Titled-.jpg?width=250&height=187 Xenon Pharmaceuticals, Steel Dynamics, Nucor And Other Big Stocks Moving Lower In Friday’s Pre-Market Session Xenon Pharmaceuticals (NASDAQ:XENE) shares fell 27.6% to $41.51 in pre-market trading following the company's announcement of a temporary pause in enrollment for new patients in its psychiatry studies due to neuropsychiatric adverse events. Other notable declines included Steel Dynamics (NASDAQ:STLD), which dropped 4.5% to $234.42, despite projecting a third-quarter EPS increase to $5.34-$5.38 from $3.69 in the previous quarter. Nucor Corp (NYSE:NUE) also saw a decline of 3.1% to $257.00, while forecasting third-quarter earnings of $5.55 to $5.65 per diluted share, up from $2.63 a year ago. https://openbell.ai/news/GOOGL:1789732590323 2026-09-18T11:56:30.323Z daily 0.9 https://cdn.brandfetch.io/GOOGL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Tigress Financial Maintains Strong Buy on Alphabet, Raises Price Target to $485 Tigress Financial analyst Ivan Feinseth has maintained a Strong Buy rating on Alphabet (NASDAQ: GOOGL) and increased the price target from $415 to $485. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/INTC:1789732533322 2026-09-18T11:55:33.322Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Santa-Clara--Ca--Usa---Nov-22--2023-Inte.jpg?width=250&height=187 Why Is Intel Stock Gaining Friday? Intel Corp. (NASDAQ: INTC) stock rose 1.22% to $110.13 in premarket trading on Friday, supported by reports of SK hynix Inc. potentially partnering with Intel to produce memory chips in the U.S. The stock is currently trading above its 20-day and 200-day simple moving averages, although it remains below its 50-day average, indicating some short-term weakness. Analysts have a consensus Hold rating on Intel, with price forecasts ranging from $110 to $145. https://openbell.ai/news/AGEN:1789732434784 2026-09-18T11:53:54.784Z daily 0.9 https://cdn.brandfetch.io/AGEN/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chardan Capital Initiates Coverage On Agenus with Buy Rating, Announces Price Target of $40 Chardan Capital analyst Andreas Argyrides has initiated coverage on Agenus (NASDAQ: AGEN) with a Buy rating. The firm has set a price target of $40 for the stock. https://openbell.ai/news/CUE:1789732385905 2026-09-18T11:53:05.905Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Side-View-Of-Concentrated-Crypto-Trader-.jpg?width=250&height=187 This Cue Biopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday B. Riley Securities analyst Mayank Mamtani initiated coverage on Cue Biopharma Inc (NASDAQ: CUE) with a Buy rating and set a price target of $83, while the stock closed at $37.84 on Thursday. This initiation is part of a broader trend where analysts are adjusting their ratings on various companies, including First Tracks Biotherapeutics and Boyd Group Services, with price targets significantly above their current closing prices. https://openbell.ai/news/MASK:1789732300396 2026-09-18T11:51:40.396Z daily 0.9 https://cdn.brandfetch.io/MASK/w/400/h/400?c=1idopYfmtR7ZKg8QMud 3 E Network Technology Announces Completion Of Pre-Silicon Hardware Emulation For Custom Edge AI Chip Used In Aladdin Healthcare Robots openbell Financial News https://openbell.ai/news/AAPL:1789732105922 2026-09-18T11:48:25.922Z daily 0.9 https://cdn.brandfetch.io/AAPL/w/400/h/400?c=1idopYfmtR7ZKg8QMud Evercore ISI Group Maintains Outperform on Apple, Raises Price Target to $380 Evercore ISI Group analyst Amit Daryanani has maintained an 'Outperform' rating on Apple (NASDAQ: AAPL) and raised the price target from $365 to $380. This adjustment reflects a positive outlook on the company's performance. https://openbell.ai/news/NFLX:1789731931631 2026-09-18T11:45:31.631Z daily 0.9 https://cdn.brandfetch.io/NFLX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Netflix shares are trading lower after Wells Fargo downgraded the stock from Equal-Weight to Underweight and cut its price target from $80 to $57. openbell Financial News https://openbell.ai/news/WHLR:1789731835823 2026-09-18T11:43:55.823Z daily 0.9 https://cdn.brandfetch.io/WHLR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wheeler Real Estate Investment Trust shares are trading lower after the company announced a 1-for-9 reverse stock split. openbell Financial News https://openbell.ai/news/RARE:1789731729189 2026-09-18T11:42:09.189Z daily 0.9 https://cdn.brandfetch.io/RARE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA Ultragenyx Pharmaceutical Inc. announced that the FDA has granted standard full approval for FAYUVI (rebisufligene etisparvovec-hopf), the first-ever treatment for pediatric patients with mucopolysaccharidosis type IIIA (Sanfilippo syndrome Type A). This marks Ultragenyx's second gene therapy approval and sixth overall FDA approval. The company plans to ship the commercial product to Qualified Treatment Centers within 30-60 days and received a Priority Review Voucher upon approval. https://openbell.ai/news/XENE:1789731630487 2026-09-18T11:40:30.487Z daily 0.9 https://cdn.brandfetch.io/XENE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Xenon Pharmaceuticals shares are trading lower after the company announced it voluntarily initiated a temporary pause of enrollment of new patients in ongoing psychiatry studies. Multiple firms lowered their respective price targets on the stock. openbell Financial News https://openbell.ai/news/XENE:1789731613615 2026-09-18T11:40:13.615Z daily 0.9 https://cdn.brandfetch.io/XENE/w/400/h/400?c=1idopYfmtR7ZKg8QMud Deutsche Bank Downgrades Xenon Pharmaceuticals to Hold, Lowers Price Target to $46 Deutsche Bank analyst David Hoang has downgraded Xenon Pharmaceuticals (NASDAQ: XENE) from a Buy rating to Hold. The price target for the stock has been reduced significantly from $90 to $46. https://openbell.ai/news/HUBS:1789731209345 2026-09-18T11:33:29.345Z daily 0.9 https://cdn.brandfetch.io/HUBS/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on HubSpot, Maintains $300 Price Target Needham analyst Joshua Reilly has reiterated a Buy rating on HubSpot (NYSE: HUBS) and maintained a price target of $300 for the company's stock. This endorsement reflects confidence in HubSpot's market position and potential for growth. https://openbell.ai/news/WPC:1789731112869 2026-09-18T11:31:52.869Z daily 0.9 https://cdn.brandfetch.io/WPC/w/400/h/400?c=1idopYfmtR7ZKg8QMud W. P. Carey Raises Quarterly Dividend From $0.94 To $0.95/Share openbell Financial News https://openbell.ai/news/NFLX:1789731001161 2026-09-18T11:30:01.161Z daily 0.9 https://cdn.brandfetch.io/NFLX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Wells Fargo Downgrades Netflix to Underweight, Lowers Price Target to $57 Wells Fargo analyst Steven Cahall has downgraded Netflix (NASDAQ: NFLX) from Equal-Weight to Underweight. The price target for the stock has been reduced from $80 to $57. https://openbell.ai/news/USO:1789730669066 2026-09-18T11:24:29.066Z daily 0.9 https://cdn.brandfetch.io/USO/w/400/h/400?c=1idopYfmtR7ZKg8QMud 'Saudis Tell European Refiners They’ll Get No Crude Next Month' - Bloomberg Saudi Arabia has informed European refiners that they will not receive any crude oil shipments next month, a move that could significantly impact oil supply in the region. This decision follows the Kingdom's ongoing strategy to manage oil production levels amid fluctuating global demand. The announcement may lead to increased oil prices as refiners seek alternative sources to meet their needs. https://openbell.ai/news/TCRT:1789730654779 2026-09-18T11:24:14.779Z daily 0.9 https://cdn.brandfetch.io/TCRT/w/400/h/400?c=1idopYfmtR7ZKg8QMud Market-Moving News for September 18th Alaunos Therapeutics (TCRT) filed a patent application for the identification of neoantigen-reactive T cell receptors, causing its stock to rise by 69%. DataMeds AI (MEDS) settled litigation related to outstanding debt and receivables, retiring approximately 364,099 shares and paying $450,000 in cash, resulting in a 24% increase in its stock price. Conversely, Xenon Pharmaceuticals (XENE) saw a 26% decline in its stock after announcing a temporary pause in the enrollment of new patients in ongoing psychiatry studies. https://openbell.ai/news/NGVC:1789730552096 2026-09-18T11:22:32.096Z daily 0.9 https://cdn.brandfetch.io/NGVC/w/400/h/400?c=1idopYfmtR7ZKg8QMud B of A Securities Initiates Coverage On Natural Grocers with Buy Rating, Announces Price Target of $35 B of A Securities analyst Vicky Liu has initiated coverage on Natural Grocers (NYSE: NGVC) with a Buy rating. The firm has set a price target of $35 for the stock. https://openbell.ai/news/ONON:1789730510965 2026-09-18T11:21:50.965Z daily 0.9 https://cdn.brandfetch.io/ONON/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on On Holding, Maintains $37 Price Target Needham analyst Tom Nikic has reiterated a Buy rating on On Holding (NYSE: ONON) and maintained a price target of $37 for the stock. This endorsement reflects confidence in the company's performance and market position. https://openbell.ai/news/DKNG:1789730218482 2026-09-18T11:16:58.482Z daily 0.9 https://cdn.brandfetch.io/DKNG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Needham Reiterates Buy on DraftKings, Maintains $35 Price Target Needham analyst Bernie McTernan has reiterated a Buy rating on DraftKings (NASDAQ: DKNG) and maintained a price target of $35. This endorsement reflects confidence in the company's performance and market position. https://openbell.ai/news/DKNG:1789729885688 2026-09-18T11:11:25.688Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/The-DraftKings-Trade.jpg?width=250&height=187 What's Going On With DraftKings Stock on Friday? DraftKings Inc. (NASDAQ: DKNG) shares rose 0.67% to $22.62 during Friday's premarket trading as investors reacted to NBA star LeBron James switching from DraftKings to Polymarket in a $15 million deal. The stock remains in a downtrend, trading significantly below key moving averages, with estimates for the upcoming earnings report on November 5, 2026, predicting a loss of 16 cents per share on revenue of $1.42 billion. Analysts maintain a Buy rating for DKNG, with an average price target of $34.14. https://openbell.ai/news/BLSM:1789729700070 2026-09-18T11:08:20.070Z daily 0.9 https://cdn.brandfetch.io/BLSM/w/400/h/400?c=1idopYfmtR7ZKg8QMud BlossomHill Therapeutics Q2 EPS $(8.75) BlossomHill Therapeutics (NASDAQ: BLSM) reported a Q2 loss of $(8.75) per share, which represents a 58.8% increase in losses compared to $(5.51) per share in the same quarter last year. https://openbell.ai/news/TRUG:1789729665575 2026-09-18T11:07:45.575Z daily 0.9 https://cdn.brandfetch.io/TRUG/w/400/h/400?c=1idopYfmtR7ZKg8QMud TruGolf Links Announces Tokenized Equipment Leasing And Fractional Franchise Ownership Plans With Polymath, Contingent On Pending Acquisition Close openbell Financial News https://openbell.ai/news/SVAQ:1789729644577 2026-09-18T11:07:24.577Z daily 0.9 https://cdn.brandfetch.io/SVAQ/w/400/h/400?c=1idopYfmtR7ZKg8QMud EigenQ Secures $45M Convertible Note Financing To Advance Commercialization Ahead Of SVAQ Merger EigenQ, Inc. has secured $45 million in convertible note financing to support its commercialization efforts ahead of its merger with Silicon Valley Acquisition Corp. (SVAQ). The financing includes an upfront funding of $22.5 million, with the remainder expected to be funded upon completion of the merger, which values the combined entity at an estimated $3 billion. The merger is anticipated to close in the fourth quarter of 2026, subject to shareholder and regulatory approvals, and aims to enhance EigenQ's capital access while allowing existing shareholders to maintain significant ownership. https://openbell.ai/news/BSEM:1789729632891 2026-09-18T11:07:12.891Z daily 0.9 https://cdn.brandfetch.io/BSEM/w/400/h/400?c=1idopYfmtR7ZKg8QMud BioStem Technologies Announces $40M Committed Equity Facility With Roth Principal Investments For Working Capital, General Corporate Purposes openbell Financial News https://openbell.ai/news/OKLO:1789729575526 2026-09-18T11:06:15.526Z daily 0.9 https://cdn.brandfetch.io/OKLO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Why Is Oklo Stock Gaining Friday? Oklo Inc. (NYSE: OKLO) stock rose 0.63% to $39.90 in premarket trading as investors showed renewed interest in nuclear power stocks following the U.S. House's passage of the Ratepayer Protection Act. This bill aims to manage rising electricity costs associated with increased demand from AI data centers, highlighting the potential for nuclear energy solutions. Despite the gain, Oklo's stock remains in a longer-term downtrend, trading below key moving averages, with a consensus Buy rating and an average price target of $85.46. https://openbell.ai/news/CATO:1789729547053 2026-09-18T11:05:47.053Z daily 0.9 https://cdn.brandfetch.io/CATO/w/400/h/400?c=1idopYfmtR7ZKg8QMud Cato Corporation To Close ~70 Additional Underperforming Stores In Q3 And Q4; Brings FY26 Total Planned Stores Closures To ~120; Sees $1M-$1.3M In Associated Costs Cato Corporation plans to close approximately 70 additional underperforming stores in Q3 and Q4, bringing the total planned store closures for FY26 to around 120. The company anticipates incurring costs between $1 million and $1.3 million associated with these closures, primarily for disposing of signage and fixtures. These closures are part of an annual review process of store performance, and the company expects that this strategy will positively impact operating results in fiscal 2027 and beyond. https://openbell.ai/news/OKLO:1789729519823 2026-09-18T11:05:19.823Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Konskie--Poland---August-03--2025-Oklo-C.jpg?width=250&height=187 Why Is Oklo Stock Gaining Friday? Oklo Inc. (NYSE: OKLO) stock rose 0.63% to $39.90 in premarket trading as investors showed renewed interest in nuclear power stocks following the U.S. House's passage of the Ratepayer Protection Act, which aims to mitigate rising electricity costs. The bill highlights the potential for nuclear and advanced reactor developers to supply reliable energy for AI data centers. Despite the gain, Oklo's stock remains in a longer-term downtrend, trading below several key moving averages, with a Buy consensus rating and an average price forecast of $85.46. https://openbell.ai/news/BRR:1789729448866 2026-09-18T11:04:08.866Z daily 0.9 https://cdn.brandfetch.io/BRR/w/400/h/400?c=1idopYfmtR7ZKg8QMud ProCap Financial To Join Russell 2000 And Russell 3000 Indexes, Effective September 21 ProCap Financial will be added to the Russell 2000 and Russell 3000 indexes effective September 21, 2026. The company has seen significant growth in its AI agent lab, Silvia, which has connected over $60 billion in assets and converted 25% of its monthly active users to paying subscribers since its launch in May 2025. Additionally, ProCap Financial will rename itself Silvia, Inc. and begin trading under the ticker 'SVIA' starting September 22, 2026. https://openbell.ai/news/MG:1789729361981 2026-09-18T11:02:41.981Z daily 0.9 https://cdn.brandfetch.io/MG/w/400/h/400?c=1idopYfmtR7ZKg8QMud MISTRAS Group Agrees To Be Acquired By Affiliates Of H.I.G. Capital In All-Cash Transaction, Representing Enterprise Value Of ~$866M, Including Outstanding Debt MISTRAS Group, Inc. has entered into a definitive agreement to be acquired by affiliates of H.I.G. Capital in an all-cash transaction valued at approximately $866 million, including outstanding debt. Stockholders will receive $20.35 per share, representing an 8% and 13% premium to the Company’s 30 and 90-day average share prices, respectively. The transaction has been unanimously approved by MISTRAS's Board of Directors and is expected to close in late 2026 or early 2027, pending stockholder and regulatory approvals. A 40-day 'go-shop' period is in place for alternative acquisition proposals. https://openbell.ai/news/MU:1789729332507 2026-09-18T11:02:12.507Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) stock rose 1.23% to $989.50 in premarket trading, continuing a strong performance with a 478.78% increase over the past year. The company is expanding U.S. memory production with new facilities in Boise, Idaho, and Clay, New York, amid a global supply shortage. Analysts maintain a Buy consensus rating, with an average price forecast of $1,521.74, although some have adjusted their forecasts lower. The stock is currently trading above its 20-day, 50-day, and 200-day moving averages, indicating a long-term uptrend. https://openbell.ai/news/MU:1789729323487 2026-09-18T11:02:03.487Z daily 0.9 https://cdn.brandfetch.io/MU/w/400/h/400?c=1idopYfmtR7ZKg8QMud What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) stock increased by 1.23% to $989.50 in premarket trading, benefiting from a stronger technology sector. Over the past year, Micron shares have surged 478.78%, and the company is set to release its earnings report on September 30. Micron is expanding its U.S. memory production with new facilities in Boise, Idaho, and Clay, New York, amid a global supply shortage, although the industry faces a potential shortage of skilled workers. Analysts maintain a Buy consensus rating with price forecasts ranging from $1,150 to $1,521.74. https://openbell.ai/news/CAVA:1789729271141 2026-09-18T11:01:11.141Z daily 0.9 https://cdn.brandfetch.io/CAVA/w/400/h/400?c=1idopYfmtR7ZKg8QMud CAVA Group Board Approves $100M Share Repurchase Program CAVA Group, Inc. has announced a $100 million share repurchase program approved by its board of directors. The program allows for repurchases in the open market or through privately negotiated transactions, with flexibility in timing and amount based on market conditions. It is set to expire on September 17, 2027, and will be funded through existing cash and operational cash flows. https://openbell.ai/news/MU:1789729255814 2026-09-18T11:00:55.814Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Los-Angeles--California---24-January-202.jpg?width=250&height=187 What's Going On With Micron Technology Stock Friday? Micron Technology Inc. (NASDAQ: MU) saw its stock rise 1.23% to $989.50 in premarket trading, benefiting from a positive technology sector backdrop. Over the past year, Micron's shares have surged 478.78%, and the company is preparing for its earnings report on September 30. Additionally, Micron is expanding its U.S. production capabilities with new facilities in Boise, Idaho, and Clay, New York, amid a global memory supply shortage, although the industry faces a potential shortage of skilled workers. Analysts maintain a Buy consensus rating for Micron, with an average price forecast of $1,521.74. https://openbell.ai/news/MTN:1789729092037 2026-09-18T10:58:12.037Z daily 0.9 https://cdn.benzinga.com/files/images/story/2026/09/18/Konskie--Poland---March-01--2025-Vail-Re.jpg?width=250&height=187 Vail Resorts Likely To Report Q4 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call Vail Resorts, Inc. (NYSE: MTN) is expected to report a quarterly loss of $5.25 per share for Q4, compared to a loss of $5.08 per share in the same period last year. The consensus revenue estimate is $273.16 million, slightly up from $271.29 million reported last year. Shares of Vail Resorts fell 1.7% to close at $137.76 on Thursday. Recent analyst ratings show a mix of maintained and adjusted price targets, with JP Morgan raising its target to $126 and Truist cutting it to $195. https://openbell.ai/news/MRK:1789729067695 2026-09-18T10:57:47.695Z daily 0.9 https://cdn.brandfetch.io/MRK/w/400/h/400?c=1idopYfmtR7ZKg8QMud EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Merck's KEYTRUDA in combination with Padcev for the treatment of adults with resectable muscle-invasive bladder cancer (MIBC). This recommendation is based on positive results from the Phase 3 KEYNOTE-B15 trial, which showed improvements in event-free survival, overall survival, and pathologic complete response rates. If approved, this regimen would be the first PD-1 inhibitor plus antibody-drug conjugate treatment for MIBC patients in the EU, with a final decision from the European Commission expected by the fourth quarter of 2026.